Q3 2017 Earnings Estimate for AxoGen, Inc. Issued By Wedbush (AXGN)
AxoGen, Inc. (NASDAQ:AXGN) – Equities research analysts at Wedbush decreased their Q3 2017 EPS estimates for AxoGen in a research note issued on Thursday. Wedbush analyst Levy. T now expects that the medical equipment provider will post earnings per share of ($0.10) for the quarter, down from their prior estimate of ($0.09). Wedbush currently has a “Outperform” rating and a $14.00 price objective on the stock. Wedbush also issued estimates for AxoGen’s Q4 2017 earnings at ($0.14) EPS, FY2017 earnings at ($0.42) EPS, FY2018 earnings at ($0.22) EPS and FY2019 earnings at $0.10 EPS.
AxoGen (NASDAQ:AXGN) last released its earnings results on Wednesday, August 2nd. The medical equipment provider reported ($0.06) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.02. AxoGen had a negative return on equity of 114.64% and a negative net margin of 27.50%. The firm had revenue of $15.20 million during the quarter, compared to the consensus estimate of $14.40 million. During the same quarter in the previous year, the company posted ($0.09) earnings per share. The company’s revenue was up 46.2% compared to the same quarter last year.
A number of other research analysts also recently issued reports on AXGN. ValuEngine upgraded AxoGen from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Cantor Fitzgerald started coverage on AxoGen in a research note on Thursday, June 29th. They set an “overweight” rating and a $18.00 price target on the stock. BidaskClub downgraded AxoGen from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Finally, Leerink Swann started coverage on AxoGen in a research note on Monday, July 31st. They set an “outperform” rating and a $22.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $15.90.
Shares of AxoGen (AXGN) opened at 14.65 on Monday. AxoGen has a 12-month low of $6.51 and a 12-month high of $17.25. The company’s 50 day moving average price is $15.87 and its 200-day moving average price is $12.68. The firm’s market cap is $486.97 million.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State Street Corp boosted its stake in AxoGen by 12.8% in the fourth quarter. State Street Corp now owns 352,735 shares of the medical equipment provider’s stock worth $3,175,000 after buying an additional 39,963 shares during the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in AxoGen by 17.3% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 19,903 shares of the medical equipment provider’s stock worth $179,000 after buying an additional 2,935 shares during the last quarter. AQR Capital Management LLC bought a new stake in AxoGen during the fourth quarter worth $180,000. Teachers Advisors LLC boosted its stake in AxoGen by 25.5% in the fourth quarter. Teachers Advisors LLC now owns 48,740 shares of the medical equipment provider’s stock worth $439,000 after buying an additional 9,893 shares during the last quarter. Finally, Bank of Montreal Can boosted its stake in AxoGen by 978.5% in the first quarter. Bank of Montreal Can now owns 14,981 shares of the medical equipment provider’s stock worth $157,000 after buying an additional 13,592 shares during the last quarter. Hedge funds and other institutional investors own 64.58% of the company’s stock.
Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.